HomeSimvastatinSimvastatin + Drospirenone And Estradiol

Does Simvastatin Interact with Drospirenone And Estradiol?

Simvastatin and Drospirenone And Estradiol have a unknown drug interaction according to U.S. FDA drug labeling data. Two further clinical drug-drug interaction studies using simvastatin and midazolam as marker substrates for CYP3A4, respectively, were performed and the results of these studies demonstrated that pharmacokinetics of the CYP3A4 substrates were not influenced by steady-state DRSP concentrations. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.

Severity
Unknown
Simvastatin Class
HMG-CoA Reductase Inhibitor
Drospirenone And Estradiol Class
Estrogen
Management
Consult your pharmacist
Data Source
U.S. FDA via OpenFDA

What To Tell Your Doctor or Pharmacist

If you are taking Simvastatin and your doctor is considering prescribing Drospirenone And Estradiol (or vice versa), make sure to:

  • Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
  • Ask whether the benefits of combining these medications outweigh the risks for your specific situation
  • Ask what symptoms to watch for that would indicate the interaction is causing problems
  • Never stop or change either medication without first consulting your healthcare provider
💊 Simvastatin+💊 Drospirenone And Estradiol(Angeliq)

Severity & Interaction Details

ℹ️
unknown
Interaction documented — severity unclassified
The FDA label notes an interaction but the severity is not classified in our dataset.
Severity scale
MinorContra
On record
Yes
Drug A class
HMG-CoA Reductase Inhibitor
Drug B class
Estrogen
Source
FDA drug label - drospirenone and estradiol

What this means in plain English

Two further clinical drug-drug interaction studies using simvastatin and midazolam as marker substrates for CYP3A4, respectively, were performed and the results of these studies demonstrated that pharmacokinetics of the CYP3A4 substrates were not influenced by steady-state DRSP concentrations.

Share this result:XFacebookWhatsAppReddit
Add more drugs
Check Simvastatin and Drospirenone And Estradiol against your full medication list

Most patients take more than two medications. CDI checks every pair across up to 20 drugs simultaneously — including OTCs and common supplements.

Add more drugs →

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine. For informational purposes only. Always consult your pharmacist or physician.